Search results
Results from the WOW.Com Content Network
The treatment of colorectal cancer can be aimed at cure or palliation. The decision on which aim to adopt depends on various factors, including the person's health and preferences, as well as the stage of the tumor. [140] Assessment in multidisciplinary teams is a critical part of determining whether the patient is suitable for surgery or not ...
Treatments may be attempted until symptoms are satisfactorily controlled. A treatment algorithm based upon the cause has been proposed, including conservative, non-operative and surgical measures (neosphincter refers to either dynamic graciloplasty or artificial bowel sphincter, lavage refers to retrograde rectal irrigation). [2] Incontinence ...
The extent of diarrhea is graded based on severity, from 1 to 5. Grade 1 diarrhea is defined by an increase in the number of stools below four per day (compared with baseline). Grade 2 diarrhea is defined by an increase of 4–6 bowel movements per day. Grade 3 diarrhea is defined by an increase by 7 or more bowel movements per day.
Bowel management is the process which a person with a bowel disability uses to manage fecal incontinence or constipation. [1] People who have a medical condition which impairs control of their defecation use bowel management techniques to choose a predictable time and place to evacuate. [ 1 ]
Cancer Research UK note that superfoods are often promoted as having an ability to prevent or cure diseases, including cancer; they caution, "a healthy, balanced and varied diet can help to reduce the risk of cancer but it is unlikely that any single food will make a major difference on its own."
Low anterior resection syndrome (LARS) comprises a collection of symptoms mainly affecting patients after surgery for rectal cancer characterized by fecal incontinence (stool and gases), fecal urgency, frequent bowel movements and bowel fragmentation, while some patients only experience constipation and a feeling of incomplete bowel emptying.
The anti-TNF-α monoclonal antibody infliximab is a major biological therapy for inflammatory bowel disease. Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. [1]
The lower bowel may be treated directly with radiation (treatment of rectal or anal cancer) or be exposed by radiation therapy to other pelvic structures (prostate, bladder, female genital tract). Typical symptoms are soreness, diarrhoea, and nausea. Nutritional interventions may be able to help with diarrhoea associated with radiotherapy. [25]